On December 3, 2015 Cellectis (Alternext: ALCLS – Nasdaq: CLLS) reported that it will host a conference call with Pfizer Inc. (PFE) and Servier on Monday, December 7, 2015 at 8:00 a.m. Eastern Time to discuss their previously announced UCART19 development collaboration (Press release, Cellectis, DEC 3, 2015, View Source [SID:1234508394]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

UCART19 is a TALEN gene-edited allogeneic Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy developed by Cellectis. On November 19, 2015, Servier exercised its worldwide licensing option with Cellectis to UCART19 and entered into a global UCART19 license and collaboration agreement with Pfizer.

Conference Call Information
Cellectis, Pfizer and Servier management will host a conference call on Monday, December 7, 2015 at 8:00 a.m. ET to discuss UCART19 three-party collaboration.

Dial-In Numbers:
Live Participant Dial-In (Toll-Free US & Canada): 877-407-3104
Live Participant Dial-In (International): +1 201-493-6792
Replay Information:
Conference ID #: 13625168
Replay Dial-In (Toll Free US & Canada): 877-660-6853
Replay Dial-In (International): +1 201-612-7415
Expiration Date: 12/21/15
Webcast URL (Archived for 12 months):
http://cellectis.equisolvewebcast.com/12-7-UCART19